2016-11-19T05-04-49Z
Source: International Journal of Basic & Clinical Pharmacology
Elavarasi Pichai, Ezhil Ramya J., Vasanth Sandanapitchai.
Background: Heart rate is the important key factor for determining the cardiac output, myocardial oxygen demand and coronary blood flow. Reduction in heart rate is the main stay of treatment for preventing and treating IHD. Due to the interactions with other drugs and adverse effects of the conventional drugs, the management of IHD focused on novel targets. Ivabradine is a novel specific and selective if current inhibitor of SA node. The objective of the study was to efficacy and safety of ivabradine as an add-on to atenolol in patients with chronic stable ischemic heart disease. Methods: Interventional, open label, prospective clinical study was done over a period of 1 year. Single centered study conducted in 50 patients in the Outpatient Department of cardiology, Tirunelveli Medical College Hospital, Tirunelveli. Endpoints noted were reduction in resting heart rate using 12 lead ECG and improvement in Canadian cardiovascular society (CCS) class of angina grading. Results: Ivabradine in reducing the heart rate at the end of 1 month (86.60±9.16) and at the end of 3 months (81.82±8.37) compared with baseline (93.08±11.67). CCS class of grade of angina also improved at the end of one month and 3 months compared with baseline. Grade IV (3 - 0 - 0), grade III (7 - 3 - 1) and grade II (40 - 8 - 9). Conclusions: Ivabradine is safe and effective in preventing and treating further anginal attacks in patients with chronic stable ischemic heart disease already on atenolol therapy.
http://ift.tt/2gpTS4G
Σάββατο 19 Νοεμβρίου 2016
Efficacy and safety of ivabradine as an add-on to atenolol in patients with chronic stable ischemic heart disease
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
The new app from IBM will let crowds automatically coordinates mass displays at big sporting events or protests using their smartphone camer...
-
Abstract Objective The objective of this study were to find the annual case trend of inflammatory jawbone diseases and to investigate th...
-
The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective resp...
-
by Patrick P. Lowe, Benedek Gyongyosi, Abhishek Satishchandran, Arvin Iracheta-Vellve, Aditya Ambade, Yeonhee Cho, Karen Kodys, Donna Catala...
-
http://ift.tt/2pCsm4a
-
ACS Nano DOI: 10.1021/acsnano.6b07541 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kvA0Lj via...
-
A magnetic Fe3O4/GO composite with potential for rapid solid-liquid separation through a magnetic field was synthesized using GO (graphene o...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tGBTt3 via IFTTT
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qS0o5m via IFTTT
-
Activation of class I Phosphoinositide 3-kinases (PI3Ks) by mutation or overexpression closely correlates with the development of various hu...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου